ES2646590T3 - Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos - Google Patents
Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos Download PDFInfo
- Publication number
- ES2646590T3 ES2646590T3 ES13740950.4T ES13740950T ES2646590T3 ES 2646590 T3 ES2646590 T3 ES 2646590T3 ES 13740950 T ES13740950 T ES 13740950T ES 2646590 T3 ES2646590 T3 ES 2646590T3
- Authority
- ES
- Spain
- Prior art keywords
- deletion
- point mutation
- seq
- mut
- oncogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261590089P | 2012-01-24 | 2012-01-24 | |
| US201261590089P | 2012-01-24 | ||
| PCT/US2013/022696 WO2013112549A1 (en) | 2012-01-24 | 2013-01-23 | Polynucleotides for treating oncogenic viral polypeptide positive tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2646590T3 true ES2646590T3 (es) | 2017-12-14 |
Family
ID=48873849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13740950.4T Active ES2646590T3 (es) | 2012-01-24 | 2013-01-23 | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9492526B2 (enExample) |
| EP (2) | EP3269387B1 (enExample) |
| JP (2) | JP6219849B2 (enExample) |
| KR (1) | KR102195196B1 (enExample) |
| CN (2) | CN110042110A (enExample) |
| DK (1) | DK2806889T3 (enExample) |
| ES (1) | ES2646590T3 (enExample) |
| HK (1) | HK1203833A1 (enExample) |
| IN (1) | IN2014DN06118A (enExample) |
| WO (1) | WO2013112549A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60937B1 (sr) | 2014-11-13 | 2020-11-30 | Univ Geneve | Tri-segmentirani arenavirusi kao vektori za vakcinu |
| JP7098330B2 (ja) | 2015-06-10 | 2022-07-11 | ホオキパ バイオテック ジーエムビーエイチ | Ｈｐｖワクチン |
| ES2934698T3 (es) | 2015-11-04 | 2023-02-24 | Hookipa Biotech Gmbh | Vacunas contra el virus de la hepatitis B |
| CA3003548A1 (en) | 2015-11-12 | 2017-05-18 | Hookipa Biotech Ag | Arenavirus particles as cancer vaccines |
| CA3008437A1 (en) | 2016-01-08 | 2017-07-13 | Vaccibody As | Therapeutic anticancer neoepitope vaccine |
| GB201605210D0 (en) * | 2016-03-29 | 2016-05-11 | Oxford Immunotec Ltd | Assay |
| AU2017272356A1 (en) * | 2016-06-03 | 2018-12-20 | Etubics Corporation | Compositions and methods for the treatment of human papillomavirus (HPV)-associated diseases |
| CN106655327A (zh) * | 2016-10-18 | 2017-05-10 | 云南中烟工业有限责任公司 | 一种压缩式充电装置 |
| CN109891405B (zh) * | 2016-11-11 | 2023-09-26 | 谷歌有限责任公司 | 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质 |
| IL314393A (en) | 2018-03-06 | 2024-09-01 | Precigen Inc | Human papillomavirus vaccines and uses of the same |
| CA3178325A1 (en) * | 2020-05-25 | 2021-12-02 | Soo Ok Kim | Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein |
| KR102712588B1 (ko) * | 2020-05-25 | 2024-10-02 | (주)진매트릭스 | 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
| US6864054B1 (en) * | 1998-05-26 | 2005-03-08 | Institute Of Molecular And Cell Biology | Polypeptides from CREB binding protein and related protein p300 for use in transcriptional regulation |
| BR0314529A (pt) | 2002-10-03 | 2005-08-09 | Wyeth Corp | Polipeptìdeos de papilomavìrus humano e composições imunogênicas |
| BRPI0810305A2 (pt) * | 2007-05-15 | 2018-07-10 | Transgene Sa | "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição" |
| CA2760310A1 (en) | 2009-04-28 | 2010-11-11 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CN102002105B (zh) * | 2009-09-03 | 2013-01-23 | 中国疾病预防控制中心病毒病预防控制所 | Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途 |
-
2013
- 2013-01-23 IN IN6118DEN2014 patent/IN2014DN06118A/en unknown
- 2013-01-23 EP EP17185609.9A patent/EP3269387B1/en active Active
- 2013-01-23 US US14/373,844 patent/US9492526B2/en active Active
- 2013-01-23 CN CN201910216555.2A patent/CN110042110A/zh active Pending
- 2013-01-23 EP EP13740950.4A patent/EP2806889B1/en active Active
- 2013-01-23 HK HK15104469.7A patent/HK1203833A1/xx unknown
- 2013-01-23 DK DK13740950.4T patent/DK2806889T3/da active
- 2013-01-23 ES ES13740950.4T patent/ES2646590T3/es active Active
- 2013-01-23 CN CN201380012419.2A patent/CN104159607A/zh active Pending
- 2013-01-23 KR KR1020147023589A patent/KR102195196B1/ko active Active
- 2013-01-23 WO PCT/US2013/022696 patent/WO2013112549A1/en not_active Ceased
- 2013-01-23 JP JP2014554791A patent/JP6219849B2/ja active Active
-
2016
- 2016-09-06 US US15/257,198 patent/US9969779B2/en active Active
-
2017
- 2017-09-28 JP JP2017188121A patent/JP6655051B2/ja active Active
-
2018
- 2018-04-11 US US15/950,819 patent/US20180237477A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3269387A1 (en) | 2018-01-17 |
| EP3269387B1 (en) | 2019-07-17 |
| KR20140131929A (ko) | 2014-11-14 |
| US20150023996A1 (en) | 2015-01-22 |
| HK1203833A1 (en) | 2015-11-06 |
| CN110042110A (zh) | 2019-07-23 |
| EP2806889B1 (en) | 2017-08-16 |
| US20160376324A1 (en) | 2016-12-29 |
| US9492526B2 (en) | 2016-11-15 |
| IN2014DN06118A (enExample) | 2015-08-14 |
| CN104159607A (zh) | 2014-11-19 |
| US9969779B2 (en) | 2018-05-15 |
| WO2013112549A1 (en) | 2013-08-01 |
| EP2806889A1 (en) | 2014-12-03 |
| JP2015506179A (ja) | 2015-03-02 |
| JP2018038405A (ja) | 2018-03-15 |
| EP2806889A4 (en) | 2016-04-20 |
| JP6655051B2 (ja) | 2020-02-26 |
| KR102195196B1 (ko) | 2020-12-28 |
| US20180237477A1 (en) | 2018-08-23 |
| JP6219849B2 (ja) | 2017-10-25 |
| DK2806889T3 (da) | 2017-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2646590T3 (es) | Polinucleótidos para el tratamiento de tumores positivos para polipéptidos víricos oncogénicos | |
| Dai et al. | Modified vaccinia virus Ankara triggers type I IFN production in murine conventional dendritic cells via a cGAS/STING-mediated cytosolic DNA-sensing pathway | |
| US20250109181A1 (en) | LAMP Constructs | |
| US20250313858A1 (en) | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines | |
| WO2005030971A1 (en) | Modified vaccinia virus ankara (mva) mutant and use thereof | |
| US20250066427A1 (en) | Therapeutic papilloma virus vaccines | |
| CA3111663A1 (en) | Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine | |
| US20240415951A1 (en) | Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers | |
| CA2962100C (en) | Virus-based expression vectors and uses thereof | |
| JP6382223B2 (ja) | 癌治療における、遺伝的に改変された、増強されたアポトーシス促進性を有する感染性麻疹ウイルス（ｍｖ−ｄｅｌｔａｃウイルス）の使用 | |
| Chiozzini et al. | CD8+ T cell immunogenicity induced by endogenous EVs engineered by antigens fused to a truncated Nefmut EV-anchoring protein | |
| KR20220083773A (ko) | 암 항원을 포함하는 개선된 lamp 구축물 | |
| AU2023300396A1 (en) | Epstein-barr-virus vaccine | |
| US20190282641A1 (en) | Generation of Tumor Endothelium Specific Viruses | |
| JP2014198736A (ja) | 機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種 | |
| Detu | Development of New Neural Stem Cell-Based Tumor-Targeted Gene Therapy Approaches | |
| Plumb | Cytokine and microbial regulators of T cell development, differentiation and function. |